Metazine Mr 35MG


Metazine Mr 35MG


Stock Status:

In Stock

  • Choose your option

  • *Upload Prescription

    • (max file size 80 MB)



Trimetazidine Dihydrochloride



Trimetazidine hydrochloride is suitable for adults as add-on therapy for the symptomatic treatment of patients with stable angina with first-line treatment for intolerant or poorly controlled angina pectoris.



Trimetazidine dihydrochloride is the first inhibitor of ketoacyl-CoA thiolase (KAT). KAT is a metabolic anti-ischemic drug that has proven beneficial to all coronary artery patients. Trimetazidine dihydrochloride inhibits the fatty acid pathway by inhibiting the 3keto acyl CoA thiolase and transferring oxygen to the glucose pathway. Since the glucose pathway produces energy more efficiently, the same oxygen produces more energy, making the heart more active. In addition, the aerobic oxidation of glucose prevents the production of lactic acid, thereby preventing angina pectoris.


Dosage & Administration

The recommended dose of trimetazidine is 35 mg twice a day or 20 mg tablets three times a day, taken with meals. The effect of treatment should be evaluated after three months. If there is no response to treatment, trimetazidine should be discontinued.



So far, there are no reports of drug interactions. In particular, there are no reports of interactions with β-blockers, calcium channel blockers, nitrates, heparin, hypolipidemic drugs, or digitalis preparations.



Trimetazidine is contraindicated in patients who are allergic to the active substance or any excipients. Patients suffering from Parkinson’s disease, Parkinson’s symptoms, tremor, restless leg dyskinesia, and severe renal failure are also contraindicated.


Side Effects

Trimetazidine is safe and well tolerated. Common side effects associated with trimetazidine are dizziness, headache, abdominal pain, diarrhea, indigestion, nausea, vomiting, rash, itching, hives, and weakness.


Pregnancy & Lactation

There are no data on the use of trimetazidine in pregnant women. Animal studies have not shown direct or indirect harmful effects on reproductive toxicity. As a precaution, it is best to avoid using trimetazidine during pregnancy. Whether trimetazidine is excreted in human milk is unclear. The risk to the newborn/infant cannot be ruled out. Trimetazidine should not be used during breastfeeding.


Precautions & Warnings

Trimetazidine is not a curative treatment for angina attacks, nor is it the initial treatment for unstable angina. It is also not a treatment for myocardial infarction.


Therapeutic Class

Other anti-angina and anti-ischemic drugs


Storage Conditions

Store in a dry place away from light and heat. Keep out of the reach of children.


Pharmaceutical Name

Beximco Pharmaceuticals Ltd.